Sugi Predict

Sugi Predict / Targets / AKT1S1

AKT1S1

Proline-rich AKT1 substrate 1 · Q96B36 · AKT1S1 on Sugi Atlas →

1,644 patent compounds predicted against AKT1S1, 1,002 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL10325150 SCHEMBL10325150 0.45 13/20
SCHEMBL2800011 SCHEMBL2800011 0.53 11/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL2797277) 0.52 11/20
SCHEMBL7120061 SCHEMBL7120061 0.41 5/20
SCHEMBL4362616 SCHEMBL4362616 0.38 5/20
SCHEMBL10325519 SCHEMBL10325519 0.37 5/20
SCHEMBL10194432 SCHEMBL10194432 0.58 4/20
SCHEMBL473310 SCHEMBL473310 0.39 4/20
Formic Acid Formic Acid (SCHEMBL4255370) 0.52 3/20
SCHEMBL7894701 SCHEMBL7894701 0.51 3/20
SCHEMBL3471054 SCHEMBL3471054 0.49 3/20
SCHEMBL3470901 SCHEMBL3470901 0.48 3/20
SCHEMBL5409335 SCHEMBL5409335 0.43 3/20
SCHEMBL473334 SCHEMBL473334 0.40 3/20
SCHEMBL473335 SCHEMBL473335 0.40 3/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL6017937) 0.40 3/20
SCHEMBL473373 SCHEMBL473373 0.38 3/20
SCHEMBL473375 SCHEMBL473375 0.38 3/20
SCHEMBL10315608 SCHEMBL10315608 0.31 3/20
SCHEMBL2797001 SCHEMBL2797001 0.81 2/20

Clinical trials — most relevant to AKT1S1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Addition of Everolimus to Standard of Care in Carcinoma Gallbladder PHASE2/PHASE3RECRUITING
Everolimus in Castrated Resistant Prostate Cancer(CRPC)Patients With PI3K-AKT-mTOR Signaling Pathway Deficiency PHASE3UNKNOWN
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer PHASE1/PHASE2RECRUITING
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer PHASE1/PHASE2COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
Selective Treatment According to Molecular Subtype of Prostate Cancer PHASE2UNKNOWN
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid PHASE2COMPLETED
Open Label Study of Everolimus (RAD001) in Patients With Segmental Overgrowth Syndrome PHASE2WITHDRAWN
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety PHASE2COMPLETED
STAR Cape+BKM120 MBC With Brain Met PHASE2COMPLETED
Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC) PHASE1/PHASE2COMPLETED
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas PHASE2SUSPENDED
Sirolimus to Treat Cowden Syndrome and Other PTEN Hamartomatous Tumor Syndromes PHASE2COMPLETED
MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma PHASE2COMPLETED
Dose Finding Trial of MK-7075 in Children and Adults With Proteus Syndrome PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers PHASE1COMPLETED
Palliative Thoracic Radiotherapy Plus BKM120 PHASE1COMPLETED
BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab) PHASE1COMPLETED
NGS in Gallbladder Cancer and Response to Treatment nanRECRUITING
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
Study of Proteus Syndrome and Related Congenital Disorders nanRECRUITING
PIK3CA in HER2+ BC and pCR Trial nanUNKNOWN
Molecular Phenotype Changes and Personalized Treatment for CRPC nanUNKNOWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children nanCOMPLETED
Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane nanUNKNOWN
Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors nanUNKNOWN
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) nanCOMPLETED
Protein Intake and Step Reduction in Older Adults nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a AKT1S1 binder may also engage these)

ProteinNameSimilarity
Q9D1F4 — 0.997 Q9D1F4 →
Q6AY88 — 0.993 Q6AY88 →
Q9CX62 — 0.992 Q9CX62 →
Q96EL1 — 0.991 Q96EL1 →
A2AEV7 — 0.991 A2AEV7 →
CBX6 Chromobox protein homolog 6 0.991 landscape →
Q8N350 — 0.991 Q8N350 →
Q8C1M2 — 0.990 Q8C1M2 →
Q99501 — 0.990 Q99501 →
LMTK3 Serine/threonine-protein kinase LMTK3 0.990 landscape →
ANKRD54 Ankyrin repeat domain-containing protein 54 0.990 landscape →
Q80UW3 — 0.989 Q80UW3 →
Q80UE6 — 0.989 Q80UE6 →
Q10586 — 0.989 Q10586 →
Q3KP66 — 0.989 Q3KP66 →
Q8TAP8 — 0.988 Q8TAP8 →
Q61501 — 0.988 Q61501 →
Q5TGY3 — 0.988 Q5TGY3 →
Q8VHQ2 — 0.988 Q8VHQ2 →
Q66L44 — 0.988 Q66L44 →
A2A9F4 — 0.988 A2A9F4 →
Q96J92 — 0.988 Q96J92 →
Q8K025 — 0.988 Q8K025 →
Q9P1Y5 — 0.988 Q9P1Y5 →
Q8WMS3 — 0.988 Q8WMS3 →
Q00587 — 0.987 Q00587 →
Q9ULE0 — 0.987 Q9ULE0 →
P11299 — 0.987 P11299 →
Q9BWN1 — 0.987 Q9BWN1 →
Q2THW8 — 0.987 Q2THW8 →